Playback speed
10 seconds
This video is featured in the 2024 ASCO® Annual Meeting Insights Hub
DESTINY-Breast06 - T-DXd vs. Physician’s Choice of Chemotherapy in HR+/HER2-Low/Ultralow mBC After Endocrine Therapy
736 views
June 18, 2024
Comments 0
Login to view comments.
Click here to Login